MEDCOLCANNA ORGANICS INC. AND GRUPO CURATIVA SAS ENTERED INTO A JOINT VENTURE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF CANNABIS BASED PHARMACEUTICAL PRODUCTS

MEDCOLCANNA ORGANICS INC. AND GRUPO CURATIVA SAS ENTERED INTO A JOINT VENTURE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF CANNABIS BASED PHARMACEUTICAL PRODUCTS

Bogotá, Colombia, September 10, 2020 – Medcolcanna Organics Inc. (TSXV: MCCN) through its wholly-owned subsidiary Medcolcanna SAS (“Medcolcanna”, “MCCN” or the “Company”), a leading Colombian integrated cannabis company, is pleased to announce that it has entered into a joint venture agreement for the development and commercialization of cannabis based pharmaceutical products with Grupo Curativa SAS (“Curativa”), an interdisciplinary group of physicians and scientists, internationally recognized for their development and commercialization of various carefully researched products with varying ratios of THC, CBD and other cannabinoids across human and veterinary populations. These formulas have been tested for numerous clinical conditions in over 4,000 patients over the past six years in Colombia, as well as internationally. 

MCCN’s proprietary formulations are expected to be distributed through Curativa’s network of doctors to benefit the growing patient base they have created since 2014. MCCN’s product portfolio of 12 base formulations are expected to be augmented by Curativa’s recognized 17 formulations allowing MCCN to offer science-backed products to its own network of patient clinics in Colombia as well as its other medical cannabis distribution channels around the world. Along with its 17 formulations for humans, Curativa has also developed 7 formulations for pets. MCCN will collaborate with the Curativa technical teams for reformulations and the development of new formulations. 

The joint venture expects to launch the first products in October 2020 and at such time MCCN will be producing at a commercial level. The products will be sold as magistral preparations in Colombia and MCCN will start providing its proprietary formulations to the existing network of 4,000 recurring patients under treatment by Curativa thus providing MCCN entry to an existing and rapidly growing client base. 

Average final approximate price for each product sold is estimated to be between $50 to $60 USD ($66 to $79 CAD), with total sales having the estimated potential to reach ~ 2 Million USD (2.645 M CAD) in the first full fiscal year of operation (2021). Due to the supply limitation that Curativa had, they were unable to increase the patients that they service. MCCN and Curativa are optimistic of the growth potential to satisfy a larger patient base now that supply will not be limited to the patients that can be serviced. MCCN and Curativa are also pleased to announce that they will be able to make a positive impact on patients that were not serviced in the past, and hope that they can make a positive impact on their lives. The agreement establishes cost-plus wholesale pricing, protects innovation and intellectual property with royalty payments and sets both minimum retail pricing and suggested retail pricing. The agreement also allows for up to 10% of certain retail margins to go to a foundation for the purpose of serving low-income communities. 

This joint venture agreement between MCCN and Curativa is expected to leverage MCCN’s wholly-owned subsidiary Extralia Labs’ extraction capacity to manufacture all of Curativa’s products to augment its capacity to reach its fast-growing patient network. 

The joint venture draws on Curativa’s extensive scientific and medical experience to support the development of educational programs that will expand the knowledge base about the cannabis industry and the specific nature of the benefit of some products to affect certain conditions. 

The partnership with Curativa underscores the group’s confidence in the MCCN team and its focus on establishing a best-in-class manufacturing operation with the goal of becoming a leading extraction and high-quality product formulation center in Latin America and an international supplier of medicinal-grade cannabis oil extracts, active pharmaceutical ingredients (API) and related products. 

Management Commentary 

Felipe de la Vega, CEO of Medcolcanna, commented: “This strategic alliance comes at a time when the Company has finalized its first stage in becoming a global leader in the cannabis industry by developing state of the art cultivation and extraction”.

ABOUT MEDCOLCANNA 

Medcolcanna is a Canadian integrated medical cannabis company, whose fully licensed operations are based in Colombia. Led by a proven and successful management team, Medcolcanna has facilities in optimal growing locations which positions the Company to become a global leader in the medical cannabis market. 

Medcolcanna employs state of the art organic agricultural technology and innovative pharmaceutical processes to produce high-quality products. The Company’s scalable production model and network of pharmaceutical partnerships globally ensures that they remain at the forefront of the medical cannabis industry. 

If you would like to receive News Releases via email as soon as they are published, please subscribe here: https://medcolcanna.com/contact-us/ or write to info@ medcolcanna.com. 

Additional information about Medcolcanna can be found on its web site at www. medcolcanna.com

Neither the TSX Venture Exchange Inc. nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Investor Relations Contact: 

Chris Reid, CFO 

Carrera 49b # 93-62 

Bogotá, Colombia 

Email: info@medcolcanna.com 

Felipe de la Vega, CEO 

Carrera 49b # 93-62 

Bogotá, Colombia 

Email: info@medcolcanna.com 

Forward-Looking Statements 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. 

Medcolcanna assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. 

September 10 • 2020

We have entered into a joint venture agreement for the development and commercialization of cannabis based pharmaceutical products with Grupo Curativa SAS (“Curativa”).